CLDX

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for cancer and other difficult-to-treat diseases. Headquartered in Hampton, New Jersey, the company advances a pipeline of antibody-based therapeutics designed to engage the immune system. Key programs include barzolvolimab for chronic urticaria and mast cell-driven diseases, and CDX-0159 for inflammatory conditions. Celldex leverages its expertise in immunology to create novel treatments addressing significant unmet medical needs.